
A retrospective analysis comparing the effects of two classes of renin-angiotensin-aldosterone system (RAAS)-blocking agents on Crohn's disease (CD) patients revealed significant differences. Patients taking angiotensin receptor blockers (ARBs) exhibited fewer instances of corticosteroid use over ten years compared to controls. In contrast, those on angiotensin-converting enzyme inhibitors (ACEIs) had a worse disease course, marked by more frequent imaging studies, endoscopic procedures, and gastrointestinal operations at both five and ten years. Multivariate analysis confirmed these findings, highlighting the potential benefits of ARBs over ACEIs in CD management.
Like
Save
Share